Email: cspc@cspc.cn
Media
News Center
Mar. 22
2023
VOLUNTARY ANNOUNCEMENT - SARS-CoV-2 mRNA VACCINE (SYS6006) INCLUDED FOR EMERGENCY USE IN CHINA
Mar. 13
NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF ENLONSTOBART FOR INJECTION
Mar. 11
FIRST PATIENT DOSED IN PHASE III CLINICAL TRIAL OF DUOENDA (多恩達®) (MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION) FOR THE TREATMENT OF RECURRENT METASTATIC NASO
Mar. 02
NBL-020 FOR THE TREATMENT OF ADVANCED SOLID TUMORS OBTAINS CLINIAL TRIAL APPROVAL IN CHINA
Jan. 19
Octreotide Long-Acting Injection Obtains Clinical Trial Approval
Jan. 09
levidipine Injectable Emulsion Obtains Clinical Approval
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
